Table II.

Effect of DcNP Formulation on Pharmacokinetic Parameters of Gemcitabine and Paclitaxel Administered Together in GT DcNP or Control Suspension

Parameter	Units	Gemcitabine		Ratio	Paclitaxel		Ratio
		Control	DcNP		Control	DcNP
AUC0 to ∞ a	μg min/ml	920.8	56,218.6	61.0	156.5	588.8	3.8
T1/2,app b	hr	1.6	13.7	8.6	1.8	2.0	1.1
C0 c	μg/mL	165.1	181.4	1.1	17.7	13.9	0.8
Dose/AUCd	mL/h	65.2	1.1	0.02	38.3	10.2	0.3
Vsse	mL	16.6	12.1	0.7	35.6	10.0	0.3
MRTf	hr	0.25	11.3	45.2	1.0	1.0	1.0

Pharmacokinetic parameter estimates were derived from the data shown in Fig. 1

^aNon compartmental analysis was used to estimate area under the curve (AUC) from 0 to ∞ of gemcitabine and paclitaxel in DcNP and CrEL control

^bApparent half-life was estimated from the slope of the last 3 time points collected in each condition

^cConcentration at time 0 was back extrapolated from the first time point in each condition

^dDose/AUC is shown for the relative apparent clearances of gemcitabine and paclitaxel

^eV_ss was calculated using Dose*AUMC/AUC² extrapolated to infinity

^fMean residence time (MRT) was calculated by dividing the area under the moment curve (AUMC) by the AUC from 0 to infinity